on-randomised trial of a lipid lowering drug and a steroid for the treatment of acute myeloblastic leukaemia

Completed

• Conditions: Elderly and relapsed high risk acute myeloid leukaemia; Cancer; Myeloid leukaemia

• Registration Number: ISRCTN50635541
• Lead Sponsor: niversity Hospital Birmingham NHS Foundation Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-07-25
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Patient has acute myeloid leukaemia (this can be any type of de novo or secondary AML, except acute promyelocytic leukaemia), or
2. Patient has refractory anaemia with an excess of blasts (greater than 10%) RAEB type 2 World Health Organization (WHO) criteria
3. Adult patients, either sex

Exclusion Criteria

1. Patient has acute promyelocytic leukaemia
2. Intensive chemotherapy is considered a suitable option
3. Low dose cytotoxic chemotherapy is likely to be required to control a rising blast cell count in the next month
4. Patient has a concurrent active malignancy
5. Patient has uncontrolled systemic disease (e.g. hypertension, diabetes) or severe cardiovascular disease
6. Patient is pregnant or lactating, or are potentially fertile (both males and females) and have not agreed to take adequate contraceptive precautions during the trial
7. Patient aged under 18 years

Study & Design

• Study Type: Interventional
• Study Design: Not specified